BioCryst Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on BioCryst Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date BioCryst Pharmaceuticals Inc Strategy Report
- Understand BioCryst Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioCryst Pharmaceuticals Inc (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. The company’s other pipeline products include, BCX10013 and Avoralstat. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst is headquartered in Durham, North Carolina, the US.
BioCryst Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Approved: | Peramiflu |
Rapivab (Peramivir injection): Acute uncomplicated Influenza | Rapivab |
Rapiacta (Peramivir injection): Uncomplicated seasonal influenza | Orladeyo |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In April, the company received approval from Brazilian Health Regulatory Agency (ANVISA) for Orladeyo (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. |
2024 | New Products/Services | In February, the company introduced ORLADEYO (berotralstat) for the prevention of recurrent attacks of hereditary angioedema in patients 12 years and older in Italy. |
2023 | Contracts/Agreements | In November, the company entered into a partnership with Clearside Biomedical to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector. |
Competitor Comparison
Key Parameters | BioCryst Pharmaceuticals Inc | F. Hoffmann-La Roche Ltd | GSK plc | Gilead Sciences Inc | Daiichi Sankyo Co Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United Kingdom | United States of America | Japan |
City | Durham | Basel | Brentford | Foster City | Chuo-Ku |
State/Province | North Carolina | - | England | California | Tokyo |
No. of Employees | 536 | 103,605 | 70,212 | 18,000 | 17,435 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Nancy J. Hutson | Chairman | Executive Board | 2023 | 73 |
Jon P. Stonehouse | Director; President; Chief Executive Officer | Executive Board | 2007 | 62 |
Anthony Doyle | Chief Financial Officer | Senior Management | 2020 | - |
Philip George | Chief Strategy Officer | Senior Management | 2022 | - |
Alane P. Barnes | Chief Legal Officer | Senior Management | 2018 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer